ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 11 for:    arbutus
Previous Study | Return to List | Next Study

Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02631096
Recruitment Status : Active, not recruiting
First Posted : December 15, 2015
Last Update Posted : March 5, 2018
Sponsor:
Information provided by (Responsible Party):
Arbutus Biopharma Corporation

Brief Summary:
The study is a phase 2a, single blind, randomized, placebo controlled, study evaluating the safety, anti-viral activity, and pharmacokinetics (PK) following multiple doses of intravenous ARB-001467

Condition or disease Intervention/treatment Phase
Hepatitis B, Chronic Drug: ARB-001467 Other: Placebo Phase 2

Detailed Description:
Approximately 24 subjects will be enrolled in three cohorts: two cohorts of HBeAg-negative subjects and one cohort of HBeAg-positive subjects and 12 HbeAg-negative subjects will be enrolled in cohort 4. All subjects will be non-cirrhotic, with chronic hepatitis B virus (HBV) infection, and will have been receiving nucleos(t)ide-analogue (NA) therapy with entecavir or tenofovir for at least 12 months.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Masking Description: Single Blind (Subject) in cohort 1-3, Open label in Cohort 4
Primary Purpose: Treatment
Official Title: A Phase 2a Single-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety, Anti Viral Activity, and Pharmacokinetics of ARB-001467 in Non Cirrhotic, HBeAg Negative and Positive Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy
Study Start Date : December 2015
Estimated Primary Completion Date : April 2018
Estimated Study Completion Date : April 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hepatitis B
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 0.2 mg/kg ARB-001467 or Placebo
HBeAg-negative subjects randomized 3:1 to receive ARB-001467 at 0.2 mg/kg versus placebo once a month for 3 months
Drug: ARB-001467
An IV infusion of ARB-001467
Other: Placebo
An IV infusion of placebo
Other Name: 0.9% sodium chloride
Experimental: 0.4 mg/kg ARB-001467 or Placebo
HBeAg-negative subjects randomized 3:1 to receive ARB-001467 at 0.4 mg/kg versus placebo once a month for 3 months
Drug: ARB-001467
An IV infusion of ARB-001467
Other: Placebo
An IV infusion of placebo
Other Name: 0.9% sodium chloride
Experimental: ARB-001467 or Placebo
HBeAg-positive subjects randomized 3:1 to receive ARB-001467 at 0.4 mg/kg versus placebo once a month for 3 months
Drug: ARB-001467
An IV infusion of ARB-001467
Other: Placebo
An IV infusion of placebo
Other Name: 0.9% sodium chloride
Experimental: 0.4 mg/kg ARB-001467
HBeAg-negative subjects receive ARB-001467 at. 0.4 mg/kg (open label) bi-weekly for 5 treatments and then subjects with HBsAg ≤1000 IU/mL AND ≥1.0 log10 decrease from baseline at Day 71 will continue monthly dosing through 48 weeks
Drug: ARB-001467
An IV infusion of ARB-001467



Primary Outcome Measures :
  1. Frequency and severity of treatment-emergent SAEs, discontinuations due to AEs, and laboratory abnormalities, by cohort, through 28 days after the last infusion of study treatment. [ Time Frame: 28 days post last infusion ]
    To evaluate the safety and tolerability of multiple doses of ARB-001467 in HBeAg-negative and HBeAg-positive subjects with chronic Hepatitis B virus infection who are receiving nucleos(t)ide analogue therapy


Secondary Outcome Measures :
  1. Evaluate ARB-001467 Maximum plasma concentration (Cmax) at multiple time points from baseline through Day 85; 28 days after the last infusion of study treatment (cohort 1-3) and Week 36 (Cohort 4). [ Time Frame: Up to 36 Weeks ]
    To evaluate the pharmacokinetics of multiple doses of ARB-001467 in subjects with chronic HBV infection.

  2. Evaluate ARB-001467 Time to maximum plasma concentration (Tmax) at multiple time points from baseline through Day 85; 28 days after the last infusion of study treatment (cohort 1-3) and Week 36 (Cohort 4). [ Time Frame: Up to 36 Weeks ]
    To evaluate the pharmacokinetics of multiple doses of ARB-001467 in subjects with chronic HBV infection.

  3. Evaluate ARB-001467 Area under the plasma concentration-time curve from the start of infusion to the last measurable concentration (AUC0-t) at multiple time points from baseline through Day 85 (cohort 1-3) and Week 36 (Cohort 4). [ Time Frame: Up to 36 Weeks ]
    To evaluate the pharmacokinetics of multiple doses of ARB-001467 in subjects with chronic HBV infection.

  4. Evaluate additional parameters for ARB-001467 from plasma concentration-time curve from start of infusion and extrapolated to infinity (AUC0-t), inf) partial, AUCs, T1/2, volume of distribution (VD) and clearance (CL) -baseline through Day 85 or Week 36. [ Time Frame: Up to 36 Weeks ]
    To evaluate the pharmacokinetics of multiple doses of ARB-001467 in subjects with chronic HBV infection.

  5. Evaluate antiviral activity of ARB 001467 for up to 72 weeks after the first dose of study treatment. [ Time Frame: Up to 18 months ]

    The proportion of subjects in each dose level cohort with ≥0.5 log10 HBsAg decrease from baseline at EOS, and for these subjects, the changes from baseline (expressed as percentage and log10 change) in the following virologic markers will be assessed throughout the study:

    • Quantitative HBV surface antigen (HBsAg)
    • Quantitative HBV surface antibody (HBsAb)
    • Quantitative HBV DNA and HBV-RNA (viral load)

    For the HBeAg positive cohort only:

    - Quantitative HBV e antigen (HBeAg)




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Documented chronic HBV infection for ≥12 months prior to Screening Visit.
  • Quantitative HBsAg ≥1000 IU/mL at the Screening Visit.
  • Subjects currently receiving entecavir and/or tenofovir for ≥12 months and HBV DNA undetectable.

Key Exclusion Criteria:

  • Known co-infection with HIV, hepatitis C virus, and hepatitis D virus.
  • Receiving or planning to receive systemic immunosuppressive medications during the study or ≤2 months prior to the first dose of study treatment.
  • Receiving or planning to receive interferon during the study or ≤12 months prior to the first dose of study treatment.
  • Significant immunosuppression from, but not limited to immunodeficiency conditions such as common variable hypogammaglobulinemia.
  • Clinical diagnosis of substance abuse with alcohol, narcotics, or cocaine ≤12 months prior to the Screening Visit.
  • Any known pre-existing medical or psychiatric condition that could interfere with the subject's ability to provide informed consent or participate in study conduct, or that may confound study findings.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02631096


Locations
Australia, Victoria
Monash Health, Gastroenterology and Hepatology
Clayton, Victoria, Australia, 3168
The Alfred, Gastroenterology and Hepatology
Melbourne, Victoria, Australia, 3004
Australia, Western Australia
Linear Clinical Research Ltd
Nedlands, Western Australia, Australia, 6009
New Zealand
Auckland Clinical Studies Ltd
Auckland, New Zealand, 1010
Sponsors and Collaborators
Arbutus Biopharma Corporation
Investigators
Study Chair: Patricia Mendez, MD, PhD Arbutus Biopharma Corporation

Responsible Party: Arbutus Biopharma Corporation
ClinicalTrials.gov Identifier: NCT02631096     History of Changes
Other Study ID Numbers: ARB-001467-002
First Posted: December 15, 2015    Key Record Dates
Last Update Posted: March 5, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Additional relevant MeSH terms:
Hepatitis B
Hepatitis B, Chronic
Hepadnaviridae Infections
DNA Virus Infections
Virus Diseases
Hepatitis, Viral, Human
Hepatitis
Liver Diseases
Digestive System Diseases
Hepatitis, Chronic